Senzime Expands Contract with Leading US Hospital System

Rhea-AI Summary

Senzime (STO:SEZI)(OTCQX:SNZZF) has expanded its contract with a top-10 ranked Integrated Delivery Network (IDN) healthcare system in the Southeastern United States. The new agreement extends TetraGraph monitor usage into adult care, following successful implementation in pediatric surgeries. This expansion will increase annual volumes fourfold, with 75 TetraGraph systems to be installed in operating rooms for monitoring both adults and children.

The contract reinforces Senzime's position as a trusted vendor in the US market, particularly as hospitals adopt new practice recommendations mandating quantitative neuromuscular monitoring. Senzime's TetraGraph system is used in hundreds of leading hospitals worldwide, helping anesthesiologists accurately manage neuromuscular blocking drugs and ensure safe patient recovery post-surgery.

Positive

• Expanded contract with top-10 ranked US healthcare system
• Fourfold increase in annual volumes to the IDN
• 75 TetraGraph systems to be installed in operating rooms
• Extension of TetraGraph usage from pediatric to adult care
• Reinforced position as trusted vendor in the US market
• Only vendor with guideline-compliant solutions for adults, children, and sensitive skin patients

Negative

• None.

UPPSALA, SE / ACCESSWIRE / July 19, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime, an industry leader in algorithm-based patient monitoring solutions, today announced a new contract with a leading, top-10 ranked Integrated Delivery Network (IDN) healthcare system in Southeastern United States. The contract extends TetraGraph monitor usage into adult care following successful utilization in pediatric surgeries within the IDN. With the expanded contract, the annual volumes to the IDN will increase fourfold with 75 TetraGraph systems installed in operating rooms to safely monitor adults and children.

"We continue to secure contracts with leading US hospital systems, reinforcing our position as the trusted vendor of choice in the rapidly evolving technology landscape. Contracts like this one not only affirm our industry leadership in the US market but also the dedication and expertise of our clinical and commercial teams. As hospitals now adhere to new practice recommendations mandating quantitative neuromuscular monitoring, being the only vendor with a portfolio of guideline-compliant solutions for adults, children, and patients with sensitive and fragile skin puts us in an exciting pole position," commented Philip Siberg, CEO of Senzime.

Each year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing, making accurate monitoring during surgery essential for ensuring each patient receives the appropriate dose for a safe and timely recovery.

Senzime's TetraGraph is a state-of-the-art quantitative train-of-four monitoring system used at hundreds of leading hospitals worldwide. Its proprietary technology helps anesthesiologists in accurately selecting the correct dose of neuromuscular blocking drugs and their antagonists and determining when patients have safely recovered post-surgery.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com .

Attachments

Senzime Expands Contract with Leading US Hospital System

SOURCE: Senzime

View the original press release on accesswire.com

FAQ

What is the new contract Senzime (SNZZF) announced on July 19, 2024?

Senzime announced an expanded contract with a top-10 ranked Integrated Delivery Network (IDN) healthcare system in the Southeastern United States, extending TetraGraph monitor usage into adult care and increasing annual volumes fourfold.

How many TetraGraph systems will be installed under Senzime's (SNZZF) new contract?

The expanded contract includes the installation of 75 TetraGraph systems in operating rooms to monitor both adults and children.

What is the significance of Senzime's (SNZZF) expanded contract for the company?

The contract reinforces Senzime's position as a trusted vendor in the US market, particularly as hospitals adopt new practice recommendations for quantitative neuromuscular monitoring, and demonstrates the company's leadership in providing guideline-compliant solutions.

What is the primary use of Senzime's (SNZZF) TetraGraph system?

TetraGraph is a quantitative train-of-four monitoring system used by anesthesiologists to accurately manage neuromuscular blocking drugs and ensure safe patient recovery post-surgery.